Biogen’s Gilmore O’Neill Joins Sarepta as Chief Medical Officer

16:07 EDT 13 Jun 2018 | Xconomy

Gilmore O’Neill has been appointed chief medical officer of Sarepta Therapeutics. O’Neill comes to the Cambridge, MA, biotech company from Biogen (NASDAQ: BIIB), where he was most recently senior vice president for all of the company’s clinical development. Sarepta’s first drug, eteplirsen (Exondys 51) won FDA approval in 2016 as a treatment for Duchenne muscular […]

Original Article: Biogen’s Gilmore O’Neill Joins Sarepta as Chief Medical Officer


More From BioPortfolio on "Biogen’s Gilmore O’Neill Joins Sarepta as Chief Medical Officer"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...